|
FDA, Industry to Nail Down Time for Biosimilar Fee Collection
The FDA is developing several proposals for when to collect product development fees from biosimilar makers under the user fee program being negotiated with drug companies.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives